3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns

Core Insights - Identifying and investing in early-stage biotech companies can yield significant returns, with potential for multi-fold gains if clinical trials are successful [1] - A small sub-portfolio of clinical-stage biotech stocks is recommended, as even a few successful candidates can lead to substantial wealth creation [1] Group 1: Entera Bio (ENTX) - Entera Bio has seen a 100% increase in stock price over the last 12 months, with a current market valuation of $63 million [2] - The company is developing orally delivered macromolecules, with its lead product candidate EB613 targeting high-risk, post-menopausal osteoporosis, currently in Phase 3 trials [2][3] - The addressable market for EB613 is significant, impacting over 200 million women globally, and the company is well-funded through Q3 2025, alleviating immediate dilution concerns [3] Group 2: Adicet Bio (ACET) - Adicet Bio's stock has declined by 53% in the last year, presenting a potential buying opportunity [5] - The FDA has granted fast-track designation for ADI-001 for lupus nephritis and cleared the IND application for ADI-270, the first gamma delta 1 CAR T candidate for solid tumors [5] - The company has a cash runway into the second half of 2026, indicating no dilution concerns for the next 24 months [5] Group 3: Actinium Pharmaceuticals (ATNM) - Actinium Pharmaceuticals is positioned for potential multibagger returns, with its stock remaining stable over the past year [6] - The lead product candidate, Iomab-B, is in Phase 3 trials for relapsed or refractory Acute Myeloid Leukemia, with initial results being encouraging [6][7] - Actimab-A is also in early trials for targeted therapies in the same patient population, contributing to a promising pipeline [7]